Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature

E.A.R. Theunissen; S.C.J. Bosma; C.L. Zuur; R. Spijker; S. van der Baan; W.A. Dreschler; J.P. de Boer; A.J.M. Balm; C.R.N. Rasch

doi:https://doi.org/10.1002/hed.23551

Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature

E.A.R. Theunissen, S.C.J. Bosma, C.L. Zuur, R. Spijker, S. van der Baan, W.A. Dreschler, J.P. de Boer, A.J.M. Balm, C.R.N. Rasch

Research output: Contribution to journal › Article › Academic › peer-review

59 Citations (Scopus)

Abstract

Background
Both radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT.

Methods
Comprehensive search of Medline and Embase with the terms "radiotherapy" combined with "ototoxicity," "head and neck squamous cell carcinoma," and synonyms.

Results
Of the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose.

Conclusion
The wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance.

Original language	English
Pages (from-to)	282-292
Journal	Head & neck
Volume	37
Issue number	2
DOIs	https://doi.org/10.1002/hed.23551
Publication status	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1002/hed.23551

https://pure.uva.nl/ws/files/2404368/158297_446108.pdf

Cite this

@article{41d4c91668ca4137bb40f829cab8e319,

title = "Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature",

abstract = "BackgroundBoth radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT.MethodsComprehensive search of Medline and Embase with the terms {"}radiotherapy{"} combined with {"}ototoxicity,{"} {"}head and neck squamous cell carcinoma,{"} and synonyms.ResultsOf the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose.ConclusionThe wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance.",

author = "E.A.R. Theunissen and S.C.J. Bosma and C.L. Zuur and R. Spijker and {van der Baan}, S. and W.A. Dreschler and {de Boer}, J.P. and A.J.M. Balm and C.R.N. Rasch",

year = "2015",

doi = "https://doi.org/10.1002/hed.23551",

language = "English",

volume = "37",

pages = "282--292",

journal = "Head & neck",

issn = "1043-3074",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature

AU - Theunissen, E.A.R.

AU - Bosma, S.C.J.

AU - Zuur, C.L.

AU - Spijker, R.

AU - van der Baan, S.

AU - Dreschler, W.A.

AU - de Boer, J.P.

AU - Balm, A.J.M.

AU - Rasch, C.R.N.

PY - 2015

Y1 - 2015

N2 - BackgroundBoth radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT.MethodsComprehensive search of Medline and Embase with the terms "radiotherapy" combined with "ototoxicity," "head and neck squamous cell carcinoma," and synonyms.ResultsOf the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose.ConclusionThe wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance.

AB - BackgroundBoth radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT.MethodsComprehensive search of Medline and Embase with the terms "radiotherapy" combined with "ototoxicity," "head and neck squamous cell carcinoma," and synonyms.ResultsOf the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose.ConclusionThe wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance.

U2 - https://doi.org/10.1002/hed.23551

DO - https://doi.org/10.1002/hed.23551

M3 - Article

C2 - 24478269

SN - 1043-3074

VL - 37

SP - 282

EP - 292

JO - Head & neck

JF - Head & neck

IS - 2

ER -